Genetic News

A combination therapy of gemcitabine, capecitabine and bevacizumab improves outcomes in patients with advanced pancreatic cancer, according to a multi-center study led by researchers at Roswell Park Cancer Institute in Buffalo, N.Y. Read the rest of this entry »

Patients diagnosed with pancreatic cancer – which historically carries a grim prognosis – nearly doubled their overall survival when the cancer drug Gemzar was used after surgery, new research shows. Read the rest of this entry »